Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A confirmatory phase III trial of Firdapse in patients with Lambert-Eaton myasthenic syndrome

Trial Profile

A confirmatory phase III trial of Firdapse in patients with Lambert-Eaton myasthenic syndrome

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Lambert-Eaton myasthenic syndrome
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Aug 2016 According to a Catalyst Pharmaceuticals media release, company expects to start this trial in the fourth quarter 2016 and anticipates having two clinical trial sites, one each on the east and west coasts of the U.S.The company will enroll subjects from the company's Expanded Access Programme.
    • 09 Aug 2016 According to a Catalyst Pharmaceuticals media release, company has reached an agreement with the FDA during the quarter on this trial protocol. Company anticipates filling an NDA resubmission based on the top-line data in the second half of 2017.
    • 13 Jun 2016 According to a Catalyst Pharmaceuticals media release, firdapse for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for LEMS and CMS.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top